Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2013

View Archived Issues

Epizyme presents novel epigenetic-targeted, small-molecule anticancer agents

Researchers present updated results for CART-19 cell therapy

Exploration of a key mechanistic pathway of antiapoptotic signaling in multiple myeloma

German and U.S. researchers design novel transgenic rat model for Huntington's disease

Novel agents for heart failure presented by German researchers

Novo Nordisk discloses new ligands binding to IL-21

New labeled NMDA receptor ligands patented by group in The Netherlands

Merz Pharma presents novel NMDA glycine B receptor antagonists

Novel monoclonal antibodies divulged by Antitope

Theravance synthesizes new series of neprilysin inhibitors

TRU-016 receives orphan medicinal product designation in Europe for CLL

Probuphine obtains FDA priority review designation for opioid dependence

Synergy Pharmaceuticals reports data from phase IIb/III plecanatide trial

Phase II SGI-110 trial begins in hepatocellular carcinoma

Photocure receives payment for Lumacan from Salix Pharmaceuticals

AbbVie launched as independent biopharmaceutical company

Phase IIb data presented for vaccine against enterotoxigenic bacteria

Small-molecule FADK inhibitor demonstrates efficacy for brain cancers

Results from a first-in-human phase I trial presented for AR-42

Kareus Therapeutics announces commencement of phase I trial for Alzheimer's disease candidate

Nexavar meets primary endpoint in RAI-refractory differentiated thyroid cancer

Clinical hold lifted for OncoMed's demcizumab

FDA deems complete Merck & Co's resubmission of NDA for ezetimibe/atorvastatin tablets

Relypsa reaches agreement with FDA for phase III trial of patiromer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...